243 related articles for article (PubMed ID: 28581527)
1. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract][Full Text] [Related]
2. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
4. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
5. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
6. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells.
Okuyama T; Sakamoto R; Kumagai K; Nishizawa M; Kimura T; Sugie T; Kimura T
Biochimie; 2020 Dec; 179():169-180. PubMed ID: 33022313
[TBL] [Abstract][Full Text] [Related]
7. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
8. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
9. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest.
Ishigaki H; Minami T; Morimura O; Kitai H; Horio D; Koda Y; Fujimoto E; Negi Y; Nakajima Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
Biochem Biophys Res Commun; 2019 Nov; 519(4):846-853. PubMed ID: 31558317
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
11. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
13. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.
Torres-Adorno AM; Vitrac H; Qi Y; Tan L; Levental KR; Fan YY; Yang P; Chapkin RS; Eckhardt BL; Ueno NT
Oncogene; 2019 Mar; 38(12):2135-2150. PubMed ID: 30459358
[TBL] [Abstract][Full Text] [Related]
14. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
15. ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.
Lévêque R; Corbet C; Aubert L; Guilbert M; Lagadec C; Adriaenssens E; Duval J; Finetti P; Birnbaum D; Magné N; Chopin V; Bertucci F; Le Bourhis X; Toillon RA
Cancer Lett; 2019 May; 449():196-206. PubMed ID: 30771434
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
18. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
20. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
